Ve symptoms of COVID-19 considering that the illness has no authorized remedy. Emphasis on prevention of this insalubrious self-medication amongst the COVID-19 sufferers is needed to stop complication connected to cannabis use.EthicsInstitutional approval was not expected to publish this case. Nevertheless, immediately after recovery, the patient provided a written informed consent to possess the case published and notify the community about complications of self-medications for COVID-19 symptoms.AcknowledgmentThe authors acknowledge the patient for pushing a lot to have this case published to create the neighborhood conscious.Author ContributionsAll authors created a considerable contribution to the operate reported, be it inside the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these places; took aspect in drafting, revising, or critically reviewing the short article; gave final approval of the version to be published; have agreed around the journal to which the write-up has been submitted; and agree to be accountable for all aspects with the operate.FundingFelix Bongomin’s Study function was supported by the Fogarty International Center from the National Institutes of Overall health, US Division of State’s Workplace with the US Worldwide AIDS Coordinator and Wellness Diplomacy (S/GAC), and President’s Emergency Program for AIDS Relief (PEPFAR) beneath Award Number 1R25TW011213. The content material is solely the duty of your authors and will not necessarily represent the official views with the National Institutes of Wellness.ConclusionsCannabis induced mental illness following self-medication for COVID-19 like symptoms is on the rise in theDisclosureThe authors declare that they’ve no conflicts of interest for this function.submit your manuscript | www.dovepress.comInternational Medical Case Reports Journal 2021:DovePressDovepressKaggwa et al 17. Hao F, Tan W, Jiang L, et al. Do psychiatric sufferers knowledge more psychiatric symptoms through COVID-19 pandemic and lockdown Brain. 2020;87:10006. 18. Suchithra B, As NU. Study on Awareness about Self-Medications and it really is Complications Amongst Homemakers. J Health Allied Sci. 2017;7 (01):06165. 19. Rowland TA, Marwaha S. Epidemiology and threat components for bipolar disorder. Therapeutic Adv Psychopharmacol. 2018;eight(9):25169. doi:ten.1177/2045125318769235 20. Kroon JS, Wohlfarth TD, Dieleman J, et al. Incidence rates and risk variables of bipolar Caspase 9 custom synthesis disorder in the common population: a populationbased cohort study. Bipolar Disorders. 2013;15(3):30613. doi:ten.1111/bdi.12058 21. Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh S. Cannabis use and mania symptoms: a systematic HIV-2 web review and meta-analysis. J Influence Dis. 2015;171:397. doi:ten.1016/j. jad.2014.09.016 22. Bally N, Zullino D, Aubry J-M. Cannabis Use and 1st Manic Episode. J Affect Dis. 2014;165:10308. 23. Steardo Jr L, Steardo L, Verkhratsky A. Psychiatric face of COVID-19. Translat Psychiatry. 2020;ten(1):12. 24. Rong C, Carmona NE, Lee YL, et al. Drug-drug interactions as a result of co-administering 9-THC and CBD with other psychotropic agents. Exp Opinion Drug Safety. 2018;17(1):514. doi:10.1080/14740338.2017.1397128 25. Choi KR, Heilemann MV, Fauer A, Mead M. A second pandemic: mental well being spillover from the novel coronavirus (COVID-19). J Am Psychiatric Nurs Assoc. 2020;26(four)340-343. 26. Kondo KK, Morasco BJ, Nugent SM, et al. Pharmacotherapy for the remedy of cannabis use disorder: a systematic critique. Ann Int Med. 2020;172(6):39812. doi:10.7326/M19-1105 27. Burgess C, Miller C.